StreetInsider.com News Articles

Lakefront Biotherapeutics launches €50 million share buyback program

Tue, 09 Jun 2026 16:02:27 -0400

Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) announced the launch of a share repurchase program worth up to €50 million. The program allows the company to buy back ordinary shares through December 31, 2026, with Morgan Stanley & Co International PLC facilitating the transactions.

The repurchases will occur in the open market under terms approved by an Extraordinary Shareholders' Meeting held on April 28, 2026. Aaron Cox, Chief Financial Officer of Lakefront, said the program stems from a transaction with Gilead announced in March 2026, which provided the opportunity to repurchase up to $150 million of shares subject to available distributable

Lakefront Biotherapeutics launches €50 million share buyback program

Tue, 09 Jun 2026 16:02:27 -0400

Lakefront Biotherapeutics appoints Eric Hedrick as chief medical officer

Mon, 08 Jun 2026 16:03:24 -0400

Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) appointed Eric Hedrick as chief medical officer, the company announced. Hedrick will report to CEO Henry Gosebruch and join the management committee.

The appointment supports the company's transformation following its acquisition of Ouro Medicines operational assets announced on June 4, 2026. Hedrick joined Lakefront in July 2025 as clinical evaluation lead for new pipeline opportunities.

"Eric has been an invaluable contributor over this past year, driving our clinical assessments and partnering with our external colleagues," Gosebruch said. "The Ouro portfolio is now the cornerstone of Lakefront's R&D pipeline and I'm thrilled to have a talented

Lakefront Biotherapeutics appoints Eric Hedrick as chief medical officer

Mon, 08 Jun 2026 16:03:24 -0400

Bank of America crosses 5% threshold in Lakefront Biotherapeutics

Tue, 26 May 2026 16:03:14 -0400

Bank of America Corporation (NYSE: BAC) has crossed above the 5% voting rights threshold in Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT), according to a transparency notification filed on May 20, 2026.

The threshold crossing occurred on May 13, 2026, following Bank of America's acquisition of voting rights and equivalent financial instruments in the biotherapeutics company. As of May 20, 2026, Bank of America and its affiliates owned 623,434 voting rights and 5,502,802 equivalent financial instruments, representing 9.30% of Lakefront's 65,897,071 outstanding shares.

The notification shows Bank of America holds 0.95% in direct voting rights and 8.35% through equivalent financial instruments. The

Bank of America crosses 5% threshold in Lakefront Biotherapeutics

Tue, 26 May 2026 16:03:14 -0400

The notification shows Bank of America holds 0.95% in direct voting rights and 8.35% through equivalent financial instruments. The